Developing small-molecule treatments to reverse the debilitating impact of degenerative diseases

Frequency is pioneering a new category in regenerative medicine, developing small-molecule therapeutics to selectively activate progenitor cells already present within the body to create healthy, functional tissues.

Multiple Sclerosis

Phase 1
Phase 2
Phase 3
Remyelination program

Stage: Preclinical

Expanded Access Policy

Learn about our expanded access policy.

Our Program for Multiple Sclerosis

Developing medicines that activate the cells needed to restore myelin, potentially reversing damage done by multiple sclerosis

Learn More